{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:40:52Z","timestamp":1792431652637,"version":"4.5.0"},"reference-count":98,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"national institute on drug abuse","doi-asserted-by":"publisher","award":["1UG1DA049444"],"award-info":[{"award-number":["1UG1DA049444"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"u.s. department of veterans affairs","doi-asserted-by":"publisher","award":["CIN 13-414"],"award-info":[{"award-number":["CIN 13-414"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>In the United States, despite evidence that medication treatment for OUD (MOUD) improves outcomes, buprenorphine MOUD (B-MOUD) treatment rates remain suboptimal. The Mainstreaming Addiction Treatment (MAT) Act, passed in 2022, removed federal prescribing restrictions which allowed any health care provider, including pharmacists, with a DEA (Drug Enforcement Administration) registration to prescribe B-MOUD unless otherwise restricted by their state of licensure. As of March 2026, only 16 states allow pharmacists to obtain DEA licensure for controlled substance prescriptive authority. The SUPPORT for Patients and Communities Reauthorization Act of 2025 indicates that pharmacists may prescribe B-MOUD independently where state law allows and sends a signal for states to align in this practice. Pharmacists have demonstrated the ability to provide comprehensive medication management in OUD treatment with positive outcomes of increased access, cost savings, reduced physician burden, enhanced medication utilization and adherence, improved treatment retention, and high patient satisfaction. Since implementation of the MAT Act, DEA-registered pharmacists in the Department of Veterans Affairs Veterans Health Administration (VHA) have independently prescribed B-MOUD. Clinical Pharmacist Practitioners (CPPs) within VHA practice as members of the interprofessional team and have independent prescriptive authority under a scope of practice based on their qualifications and competencies. This commentary describes CPP independent B-MOUD prescribing within VHA as an effective practice that could model pharmacist care in other large health care systems. Benefits of this model include increased B-MOUD access and retention while maintaining high quality, team-based care and use of telehealth to expand access to underserved areas. Major limitations include state legislative barriers that restrict pharmacist-controlled substance and B-MOUD prescribing. We call for advancements to state practice laws that authorize controlled substance prescriptive authority for pharmacists and reimbursement for services which are essential to continue expanding CPP B-MOUD prescribing within and beyond the VHA.<\/jats:p>","DOI":"10.1177\/29767342261467580","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T15:26:01Z","timestamp":1784474761000},"page":"963-973","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding Patient Access to Buprenorphine for Opioid Use Disorder Through Pharmacist Independent Prescriptive Authority"],"prefix":"10.1177","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-5013","authenticated-orcid":false,"given":"Michelle D.","family":"Colvard","sequence":"first","affiliation":[{"name":"VA Tennessee Valley Healthcare System, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-4703","authenticated-orcid":false,"given":"Terri L.","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Practice Office, Pharmacy Benefits Management, Veterans Health Administration, Department of Veterans Affairs, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0376-0581","authenticated-orcid":false,"given":"Veldana","family":"Alliu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Practice Office, Pharmacy Benefits Management, Veterans Health Administration, Department of Veterans Affairs, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-6545","authenticated-orcid":false,"given":"Tera D.","family":"Moore","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Practice Office, Pharmacy Benefits Management, Veterans Health Administration, Department of Veterans Affairs, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5251","authenticated-orcid":false,"given":"Haley E.","family":"Pals","sequence":"additional","affiliation":[{"name":"Tomah VA Medical Center, Tomah, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-4704","authenticated-orcid":false,"given":"Jacob D.","family":"Baylis","sequence":"additional","affiliation":[{"name":"Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA"},{"name":"Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1823-7554","authenticated-orcid":false,"given":"Michael","family":"Tran","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Practice Office, Pharmacy Benefits Management, Veterans Health Administration, Department of Veterans Affairs, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-0648","authenticated-orcid":false,"given":"Roisin M.","family":"Sabol","sequence":"additional","affiliation":[{"name":"Center for Healthcare Evaluation, Research, and Promotion, VA Pittsburgh Health Care System, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-8871","authenticated-orcid":false,"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA"},{"name":"Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1402780"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1787299"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108715"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.04.016"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.06.001"},{"key":"e_1_3_3_7_2","unstructured":"United States. Medication Access and Training Expansion (MATE) Act of 2021 S2235 117 Congress First Session. 2021."},{"key":"e_1_3_3_8_2","unstructured":"United States. SUPPORT for Patients and Communities Reauthorization Act of 2025 HR 2483 119 Congress. 2025."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016653608"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad101"},{"key":"e_1_3_3_11_2","unstructured":"State of Colorado. Treatment for Substance Use Disorders H.B. 24-1045 \u00a7 2 75th Colorado General Assembly 1st Session. 2024."},{"key":"e_1_3_3_12_2","unstructured":"Oregon So. Senate Bill 236 \u00a7 18 83rd Oregon Legislative Assembly (2025). 2025."},{"key":"e_1_3_3_13_2","unstructured":"State of Iowa. Practice of Pharmacy General Principles H.F. 555 90th Iowa General Assembly 2024."},{"key":"e_1_3_3_14_2","unstructured":"State of Virginia. Virgina Code Ann \u00a7 54.1-3300.1. 2025."},{"key":"e_1_3_3_15_2","unstructured":"State of North Dakota. Occupations and Professions Limited Prescriptive Practices S.B. 2173 64th Legislative Assembly of North Dakota Century Code \u00a7 43-15-31.4. 2015."},{"key":"e_1_3_3_16_2","unstructured":"State of Tennessee. Tennessee S.B. 2297 General Assembly of the State of Tennessee. 2024."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1787300"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107570"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2018.03.005"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190014522064"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/IPRP.S99539"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106759"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231203849"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.06.018"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1171"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2146\/news160034"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/08897077231198679"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2022.08.219"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2208055"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2015.14177"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15353"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0204"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2021.01.035"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186315"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2020.6.46452"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.03.006"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa405"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.n183353"},{"key":"e_1_3_3_39_2","unstructured":"Department of Veterans Affairs Veterans Health Administration. VHA Handbook 1108.11(4): Clinical Pharmacy Services. Department of Veterans Affairs. Accessed June 1 2025. https:\/\/www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=3120"},{"key":"e_1_3_3_40_2","unstructured":"Department of Veterans Affairs Veterans Health Administration. VHA Directive 1100.20(2): Credentialing of Health Care Providers. Department of Veterans Affairs. Accessed June 1 2025. https:\/\/www.va.gov\/vhapublications\/ViewPublication.asp?pub_ID=9444"},{"key":"e_1_3_3_41_2","unstructured":"Board of Pharmacy Specialties. BPS specialties. Accessed June 1 2025. https:\/\/bpsweb.org\/bps-specialties\/"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1177"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab011"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102530"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2020.03.011"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v73i2.2982"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.4.513"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900221117892"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa060"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.5688\/ajpe7627"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2008.07108"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181e57962"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1331\/154434506776180658"},{"issue":"5","key":"e_1_3_3_54_2","first-page":"598","article-title":"Community pharmacists as patient advocates: physician attitudes","volume":"38","author":"Bradshaw SJ","year":"1998","unstructured":"Bradshaw SJ, Doucette WR. Community pharmacists as patient advocates: physician attitudes. J am Pharm Assoc (1996). 1998;38(5):598-602.","journal-title":"J am Pharm Assoc (1996)"},{"key":"e_1_3_3_55_2","unstructured":"GIberson S Yoder S Lee MP. Improving patient and health system outcomes through advanced pharmacy practice. A report to the U.S. Surgeon General. 2011. Accessed June 1 2025. https:\/\/jcpp.net\/wp-content\/uploads\/2015\/09\/Improving-Patient-and-Health-System-Outcomes-through-Advanced-Pharmacy-Practice.pdf"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-23-488"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13142-011-0065-8"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2835-8"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1728466"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108440"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa386"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2019.07.294"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1809606"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.08.010"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/29768357251381070"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/JAN.0000000000000626"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2023.11.003"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2020.04.027"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1452327"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-018-0127-z"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001156"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00263-5"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-025-00568-9"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-06722-6"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/13561820.2025.2507968"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.43543"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2025.112663"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000739"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36914"},{"key":"e_1_3_3_80_2","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007 NSDUH Series H-60). 2025. Accessed March 1 2026. https:\/\/nhcenterforexcellence.org\/wp-content\/uploads\/2025\/08\/2024-nsduh-annual-national-report-1.pdf"},{"key":"e_1_3_3_81_2","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006 NSDUH Series H-58). 2023. Accessed March 1 2026. https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-annual-national-report"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2024.04.004"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2312906"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001457"},{"key":"e_1_3_3_85_2","volume-title":"The Complexities of Physician Supply and Demand: Projections From 2021 to 2036","author":"GlobalData Plc","year":"2024","unstructured":"GlobalData Plc. The Complexities of Physician Supply and Demand: Projections From 2021 to 2036. Association of American Medical Colleges; 2024."},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1556"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00382-1"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1694618"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1911077"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1752351"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020910838"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21073"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.7151"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.70049"},{"key":"e_1_3_3_95_2","unstructured":"Legislative Analysis and Public Policy Association. Model pharmacist collaboration for medication for opioid use disorder act. Accessed May 1 2026 https:\/\/legislativeanalysis.org\/wp-content\/uploads\/2024\/07\/Pharmacist-Collaboration-for-Medication-for-Opioid-Use-Disorder.pdf"},{"key":"e_1_3_3_96_2","unstructured":"American Society of Health-system Pharmacists. Model state law to improve access to medications for opioid use disorder from pharmacists. Accessed May 1 2026 https:\/\/www.ashp.org\/advocacy-and-issues\/key-issues\/opioids\/model-moud-prescribing-legislation?loginreturnUrl=SSOCheckOnly"},{"key":"e_1_3_3_97_2","unstructured":"National Association of Boards of Pharmacy. The pathway for pharmacists to prescribe buprenorphine directly to patients. Accessed February 26 2026 https:\/\/nabp.pharmacy\/news\/blog\/the-pathway-for-pharmacists-to-prescribe-buprenorphine-directly-to-patients\/"},{"key":"e_1_3_3_98_2","unstructured":"United States of America. Underserved Areas Enhancement Act S.2800 119th Cong. 2025."},{"key":"e_1_3_3_99_2","unstructured":"American Society of Addiction Medicine. American Society of Addiction Medicine Public Policy Statement on the Role of Pharmacists in Medications for Addiction Treatment. 2024. Accessed December 1 2024. https:\/\/www.asam.org\/advocacy\/public-policy-statements\/details\/public-policy-statements\/2024\/07\/22\/the-role-of-pharmacists-in-medications-for-addiction-treatment"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261467580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342261467580","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342261467580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:56:08Z","timestamp":1790682968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342261467580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/29767342261467580"],"URL":"https:\/\/doi.org\/10.1177\/29767342261467580","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}